home / stock / mreo / mreo news

MREO News and Press, Mereo BioPharma Group From 10/26/21

Stock Information
Company Name: Mereo BioPharma Group
Stock Symbol: MREO
Market: NASDAQ
Website: mereobiopharma.com
Menu
MREO MREO Quote MREO Short MREO News MREO Articles MREO Message Board
Get MREO Alerts

News, Short Squeeze, Breakout and More Instantly...
MREO - Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency

LONDON and REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Ad...
MREO - Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment

Living With Osteogenesis IMP erfecta: Underst A nding Experiences Based On C ommunity Insigh T and Evidence Survey, the IMPACT Survey More than 2200 individual responses collected over a 3-month period from some 65 countries in 8 lan...

MREO - Tracking Baker Brothers Portfolio - Q2 2021 Update

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

MREO - Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI Dose-dependent improvements in serum biomarkers of bone turnover with UX143 thera...
MREO - ZBRA, FGEN, GOOGL and TCOM among after hours movers

Gainers: ZBRA +7.0%. FGEN +5.0%. GOGO +4.0%. APLS +2.9%. MREO +2.6%. Losers: TCOM -9.0%. NLOK -8.3%. JCS -5.2%. GOOGL -4.8%. GNLN -4.2%. For further details see: ZBRA, FGEN, GOOGL and TCOM among after hours movers

MREO - Mereo BioPharma (MREO) Investor Presentation - Slideshow

The following slide deck was published by Mereo BioPharma Group plc in conjunction with this event. For further details see: Mereo BioPharma (MREO) Investor Presentation - Slideshow

MREO - Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jac...
MREO - Mereo BioPharma to Participate in Three Upcoming Investor Conferences

LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management’s p...

MREO - Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference

LONDON and REDWOOD CITY, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight,...

MREO - Tracking Baker Brothers Portfolio - Q1 2021 Update

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Previous 10 Next 10